Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome

We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with per...

Descripción completa

Detalles Bibliográficos
Autores principales: Xi, Bixin, Zhou, Chen, Zhang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142797/
https://www.ncbi.nlm.nih.gov/pubmed/34084507
http://dx.doi.org/10.1002/ccr3.4111
_version_ 1783696625319804928
author Xi, Bixin
Zhou, Chen
Zhang, Yu
author_facet Xi, Bixin
Zhou, Chen
Zhang, Yu
author_sort Xi, Bixin
collection PubMed
description We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with personalized low‐dose chemotherapy and subsequently remained in complete remission for 1 year.
format Online
Article
Text
id pubmed-8142797
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81427972021-06-02 Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome Xi, Bixin Zhou, Chen Zhang, Yu Clin Case Rep Case Reports We report the first case of a 12‐year‐old boy with Wiskott‐Aldrich syndrome who developed CD20‐weakly expressed and CD30‐highly expressed Epstein‐Barr virus–related post‐transplant lymphoproliferative disorder refractory to rituximab treatment. The patient was effectively and safely treated with personalized low‐dose chemotherapy and subsequently remained in complete remission for 1 year. John Wiley and Sons Inc. 2021-05-24 /pmc/articles/PMC8142797/ /pubmed/34084507 http://dx.doi.org/10.1002/ccr3.4111 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Xi, Bixin
Zhou, Chen
Zhang, Yu
Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title_full Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title_fullStr Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title_full_unstemmed Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title_short Successful low‐dose chemotherapy for refractory Epstein‐Barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with Wiskott‐Aldrich syndrome
title_sort successful low‐dose chemotherapy for refractory epstein‐barr virus—related post‐transplant lymphoproliferative disorder following hematopoietic stem cell transplantation in a child with wiskott‐aldrich syndrome
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142797/
https://www.ncbi.nlm.nih.gov/pubmed/34084507
http://dx.doi.org/10.1002/ccr3.4111
work_keys_str_mv AT xibixin successfullowdosechemotherapyforrefractoryepsteinbarrvirusrelatedposttransplantlymphoproliferativedisorderfollowinghematopoieticstemcelltransplantationinachildwithwiskottaldrichsyndrome
AT zhouchen successfullowdosechemotherapyforrefractoryepsteinbarrvirusrelatedposttransplantlymphoproliferativedisorderfollowinghematopoieticstemcelltransplantationinachildwithwiskottaldrichsyndrome
AT zhangyu successfullowdosechemotherapyforrefractoryepsteinbarrvirusrelatedposttransplantlymphoproliferativedisorderfollowinghematopoieticstemcelltransplantationinachildwithwiskottaldrichsyndrome

Ejemplares similares